BetaLife Pte Ltd has appointed Dr Natasha Hui Jin Ng (吴荟瑾博士) as Chief Scientific Officer (CSO) and acting Chief Executive Officer (CEO) with effect from 3 March 2025.
Natasha brings to BetaLife deep scientific expertise and entrepreneurial experience. She has over 12 years of experience in diabetes and islet biology research at Oxford and Singapore, and 8 years of experience in induced pluripotent stem cells. She was most recently a Senior Scientist at the Institute of Molecular and Cell Biology (IMCB) at A*STAR – Agency for Science, Technology and Research, where she was instrumental in driving the joint development of stem cell-derived pancreatic islet cells.
Natasha is a Co-Founder of BetaLife and had spent the past four years advising the company. She is well aligned with the goals and vision of the company from the get-go. She has a proven track record in leading research teams and non-profit organisations through empathetic leadership. She also comes with prior entrepreneurial experience at Oxford, and is well-networked with the local and international cell and gene therapy community.
We have every confidence that Natasha will bring renewed energy to the company and play a pivotal role in guiding our strategic vision, fostering innovation, and driving forward our mission of developing regenerative medicine solutions for diabetes.